MARKET

ADMS

Adamas Pharma
ADMS
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-3.9793
3.125
-17.3821
376,368,852.30
BRIEF-Supernus Pharma Announces Expiration Of Hart-Scott-Rodino Waiting Period For Adamas Pharma Tender Offer
reuters.com · 11/23/2021 13:35
Northland Capital Markets Downgrades Adamas Pharmaceuticals to Market Perform, Announces $8.5 Price Target
Northland Capital Markets analyst Carl Byrnes downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) from Outperform to Market Perform and announces $8.5 price target.
Benzinga · 11/17/2021 12:41
Adamis Pharmaceuticals Shares Move Higher; Traders Circulate Event Page For VirginiaBio. BZ NOTE: Co To Present Wednesday, Nov. 17
https://www.vabio.org/event/use-of-tempol-as-an-antiviral-therapeutic-against-covid-19/
Benzinga · 11/16/2021 19:33
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP is Investigating the Following Companies - BCML, GWB, ABTX, ESBK, ADMS, ACBI
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PR Newswire · 11/09/2021 18:12
Supernus up 10% following 2021 earnings guidance boost, Q3 beat
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) are up ~10% in after-hours trading after the company boosted its full-year earnings guidance and beat Q3 earnings estimates. Operating earnings for 2021 are now expected to
Seekingalpha · 11/03/2021 22:01
How Much Of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Do Institutions Own?
If you want to know who really controls Adamas Pharmaceuticals, Inc. ( NASDAQ:ADMS ), then you'll have to look at the...
Simply Wall St. · 11/02/2021 10:26
Will Adamas Pharmaceuticals (ADMS) Report Negative Q3 Earnings? What You Should Know
Zacks.com · 10/28/2021 04:41
Adamas Pharmaceuticals Shares Move Higher; Magnetar Financial Reports In 13D Filing A 6.85% Stake In Co
-SEC Filing
SEC Filing · 10/19/2021 20:29
More
No Data
Learn about the latest financial forecast of ADMS. Analyze the recent business situations of Adamas Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ADMS stock price target is 8.52 with a high estimate of 9.10 and a low estimate of 8.00.
High9.10
Average8.52
Low8.00
Current 8.22
EPS
Actual
Estimate
-0.51-0.38-0.26-0.13
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 120
Institutional Holdings: 32.50M
% Owned: 70.98%
Shares Outstanding: 45.79M
TypeInstitutionsShares
Increased
19
2.37M
New
7
133.70K
Decreased
20
2.47M
Sold Out
10
312.60K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Chairman/Lead Director/Independent Director
David Mahoney
Chief Executive Officer/Director
Neil McFarlane
Chief Financial Officer/Chief Accounting Officer
Christopher Prentiss
Other
Adrian Quartel
Other
Vijay Shreedhar
Independent Director
Michael Bigham
Independent Director
Martha Demski
Independent Director
William Ericson
Independent Director
John MacPhee
Independent Director
Spyridon Papapetropoulos
Independent Director
Anna Richo
No Data
No Data

Webull offers kinds of Adamas Pharma stock information, including NASDAQ:ADMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMS stock methods without spending real money on the virtual paper trading platform.